Rahul Aggarwal, MD

HS Assoc Clinical Professor

Hematology and Oncology UCSF Health

I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.

My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

Education
Fellowship, 2013 - Hematology/Oncology, University of California, San Francisco
Residency, 2009 - School of Medicine - Internal Medicine, University of California, San Francisco
M.D., 2006 - School of Medicine, Northwestern University Feinberg
Honors and Awards
  • Department of Defense Prostate Cancer Program Idea Development Award, 2016-2019
  • Cancer Clinical Investigator Team Leadership Award, National Cancer Institute, 2016-2017
  • Department of Defense Prostate Cancer Program Physician Research Training Award, 2016
  • Prostate Cancer Foundation Young Investigator Award, 2015-2017
  • Alliance Cooperative Group Scholar Award, 2013
  • ASCO Young Investigator Award, 2012-2013
  • Pfizer Fellowship in Oncology, 2011-2012
Publications
  1. Autoantibody landscape in patients with advanced prostate cancer.
  2. The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET.
  3. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
  4. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
  5. A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
  6. The DNA methylation landscape of advanced prostate cancer.
  7. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
  8. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
  9. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer.
  10. A novel radioligand reveals tissue specific pharmacological modulation of glucocorticoid receptor expression with positron emission tomography.
  11. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
  12. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm.
  13. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
  14. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
  15. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
  16. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
  17. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
  18. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
  19. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
  20. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
  21. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies.
  22. Reply to A. Dalla Volta et al.
  23. First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
  24. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients.
  25. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  26. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
  27. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients.
  28. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
  29. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  30. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
  31. Spatio-Temporally Constrained Reconstruction for Hyperpolarized Carbon-13 MRI Using Kinetic Models.
  32. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
  33. Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer.
  34. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
  35. Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
  36. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
  37. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
  38. Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer.
  39. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
  40. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
  41. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  42. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  43. Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
  44. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
  45. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
  46. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
  47. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
  48. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
  49. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
  50. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.
  51. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
  52. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
  53. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
  54. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
  55. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.
  56. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
  57. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
  58. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
  59. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?
  60. Approaches to minimize castration in the treatment of advanced prostate cancer.
  61. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  62. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
  63. Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
  64. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
  65. Small-cell/neuroendocrine prostate cancer: a growing threat?
  66. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
  67. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
  68. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
  69. The changing role of imaging in clinical care.
  70. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
  71. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
  72. Castration-resistant prostate cancer: targeted therapies and individualized treatment.
  73. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.